Geode Capital Management LLC Buys 40,447 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Geode Capital Management LLC lifted its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 0.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,329,996 shares of the company's stock after buying an additional 40,447 shares during the period. Geode Capital Management LLC owned about 1.98% of Hims & Hers Health worth $104,724,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after acquiring an additional 2,020,722 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after purchasing an additional 4,145,305 shares during the last quarter. State Street Corp raised its position in Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company's stock worth $85,221,000 after purchasing an additional 206,078 shares during the period. Wellington Management Group LLP lifted its stake in Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock worth $63,446,000 after purchasing an additional 883,230 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Hims & Hers Health by 7.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company's stock valued at $43,448,000 after buying an additional 129,416 shares during the period. Institutional investors own 63.52% of the company's stock.

Remove Ads

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 36,460 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $27.09, for a total value of $987,701.40. Following the transaction, the chief executive officer now owns 27,918 shares in the company, valued at $756,298.62. This represents a 56.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 54,153 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $29.90, for a total transaction of $1,619,174.70. Following the sale, the insider now owns 165,650 shares of the company's stock, valued at $4,952,935. This trade represents a 24.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 824,303 shares of company stock worth $31,376,661. Insiders own 17.71% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on HIMS shares. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Truist Financial dropped their price objective on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research note on Thursday. Needham & Company LLC upped their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Canaccord Genuity Group increased their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Finally, Piper Sandler upped their target price on Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $38.25.

Hims & Hers Health Trading Up 1.8 %

HIMS traded up $0.50 during trading on Monday, hitting $27.73. 10,463,981 shares of the company's stock traded hands, compared to its average volume of 15,128,630. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98. The company's 50 day simple moving average is $38.75 and its two-hundred day simple moving average is $30.46. The stock has a market capitalization of $6.16 billion, a price-to-earnings ratio of 63.02 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.